DexCom Benefits from the Rise of GLP-1 Medications
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy DXCM?
Source: NASDAQ.COM
- Market Opportunity: DexCom estimates that over 9 million patients in the U.S. are eligible for CGM device reimbursement but have yet to opt in, indicating a substantial market potential that, combined with the rise of GLP-1 drugs, is expected to drive demand for its devices.
- Product Complementarity: Studies show that using CGM devices alongside GLP-1 medications significantly improves health management for diabetes patients, with physicians increasingly prescribing both, further solidifying DexCom's leadership position in the market.
- Innovation and Expansion: DexCom's continuous technological innovations and market expansions have historically driven solid financial results, and with the rise of GLP-1 drugs, the company's growth outlook appears very promising.
- Investment Appeal: With the boost from GLP-1 medications, DexCom's stock is viewed as attractive, and investing $10,000 now could yield substantial returns in the future, even though the company was not included in the Motley Fool Stock Advisor's list of top stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 63.980
Low
68.00
Averages
82.54
High
100.00
Current: 63.980
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott vs. Dexcom: The CGM Market Showdown
- Market Leadership: Abbott's FreeStyle Libre has surpassed five million patients in the past three years, becoming the best-selling medical device of all time in dollar sales, showcasing its strong leadership in the CGM market, while Dexcom has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to achieve stable revenue and earnings growth with market-leading devices like MitraClip, while its acquisition in the cancer diagnostics market provides new growth opportunities.
- Competitive Dynamics: Although Dexcom has shown faster revenue growth in the CGM market, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery.
- Investment Choice: For risk-averse investors, Abbott is a better choice due to its stable dividends and market leadership, while Dexcom appeals more to risk-tolerant investors seeking high growth.
See More
Abbott vs. Dexcom: Competition in CGM Market
- Market Leadership: Abbott leads the continuous glucose monitoring (CGM) market with its FreeStyle Libre product line, which surpassed five million patient installations three years ago, demonstrating strong market penetration, while Dexcom, despite outperforming over the past decade, has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to maintain stable revenue and earnings growth, while also providing the financial resources for continued investment in the CGM market, enhancing its competitive position.
- Acquisition for Market Expansion: Abbott's $21 billion acquisition of Exact Sciences allows entry into the cancer diagnostics market, with Cologuard serving as a non-invasive colorectal cancer screening tool targeting millions of eligible individuals yet to be tested, showcasing its potential for expansion in healthcare.
- Risk vs. Reward: While Dexcom shows stronger revenue growth, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery, making it more suitable for risk-averse investors.
See More
Investment Outlook for Healthcare Tech Companies
- TransMedics Growth Potential: TransMedics Group's Organ Care System (OCS) significantly enhances organ storage and transport efficiency by mimicking human physiology, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Strategy: TransMedics plans to launch the OCS for kidneys to further expand its market, while aggressively expanding in Europe, enhancing its market opportunities, which is expected to drive performance growth over the next decade.
- Dexcom's Market Leadership: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue last year, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing its strong performance in diabetes management.
- Technological Innovation and Market Expansion: Dexcom not only leads the market among diabetes patients but also enters the over-the-counter market with the launch of Stelo, which is expected to attract more potential users and further enhance its long-term growth prospects.
See More
TransMedics and Dexcom's Market Prospects
- TransMedics Innovation: TransMedics Group's Organ Care System (OCS) mimics human physiology to significantly enhance organ storage and transport efficiency, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Opportunities: TransMedics plans to launch the OCS for kidneys to further expand its market coverage, while aggressive expansion in Europe is expected to enhance its market opportunities, driving performance growth over the next decade.
- Dexcom's Sustained Growth: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue in 2025, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing strong performance in diabetes management.
- Untapped Market Potential: Despite concerns over the popularity of GLP-1 weight loss drugs, Dexcom's management emphasizes that physicians prescribe CGM devices alongside these therapies, and the vast global market remains largely untapped, promising long-term returns for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm promises to handle cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees, thereby reducing the financial burden and encouraging more shareholders to participate.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately increases shareholder value and has significant strategic implications.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
See More
DexCom Announces Q1 2026 Financial Results Release Plan
- Earnings Release Schedule: DexCom plans to release its Q1 2026 financial results after market close on April 30, 2026, highlighting the company's ongoing innovation and development in diabetes management.
- Conference Call Details: Management will hold a conference call at 4:30 PM (Eastern Time) on the same day to review the first quarter performance, which is expected to attract significant attention from investors and analysts.
- Webcast Support: The conference call will be concurrently webcast, allowing investors to access the information through DexCom's investor relations website, ensuring transparency and accessibility of information.
- Company Background: Founded in 1999, DexCom has pioneered glucose biosensing technology for over 25 years, dedicated to empowering individuals to manage diabetes more effectively and improve their quality of life.
See More
Abbott vs. Dexcom: The CGM Market Showdown
- Market Leadership: Abbott's FreeStyle Libre has surpassed five million patients in the past three years, becoming the best-selling medical device of all time in dollar sales, showcasing its strong leadership in the CGM market, while Dexcom has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to achieve stable revenue and earnings growth with market-leading devices like MitraClip, while its acquisition in the cancer diagnostics market provides new growth opportunities.
- Competitive Dynamics: Although Dexcom has shown faster revenue growth in the CGM market, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery.
- Investment Choice: For risk-averse investors, Abbott is a better choice due to its stable dividends and market leadership, while Dexcom appeals more to risk-tolerant investors seeking high growth.
See More
Abbott vs. Dexcom: Competition in CGM Market
- Market Leadership: Abbott leads the continuous glucose monitoring (CGM) market with its FreeStyle Libre product line, which surpassed five million patient installations three years ago, demonstrating strong market penetration, while Dexcom, despite outperforming over the past decade, has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to maintain stable revenue and earnings growth, while also providing the financial resources for continued investment in the CGM market, enhancing its competitive position.
- Acquisition for Market Expansion: Abbott's $21 billion acquisition of Exact Sciences allows entry into the cancer diagnostics market, with Cologuard serving as a non-invasive colorectal cancer screening tool targeting millions of eligible individuals yet to be tested, showcasing its potential for expansion in healthcare.
- Risk vs. Reward: While Dexcom shows stronger revenue growth, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery, making it more suitable for risk-averse investors.
See More
Investment Outlook for Healthcare Tech Companies
- TransMedics Growth Potential: TransMedics Group's Organ Care System (OCS) significantly enhances organ storage and transport efficiency by mimicking human physiology, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Strategy: TransMedics plans to launch the OCS for kidneys to further expand its market, while aggressively expanding in Europe, enhancing its market opportunities, which is expected to drive performance growth over the next decade.
- Dexcom's Market Leadership: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue last year, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing its strong performance in diabetes management.
- Technological Innovation and Market Expansion: Dexcom not only leads the market among diabetes patients but also enters the over-the-counter market with the launch of Stelo, which is expected to attract more potential users and further enhance its long-term growth prospects.
See More
TransMedics and Dexcom's Market Prospects
- TransMedics Innovation: TransMedics Group's Organ Care System (OCS) mimics human physiology to significantly enhance organ storage and transport efficiency, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Opportunities: TransMedics plans to launch the OCS for kidneys to further expand its market coverage, while aggressive expansion in Europe is expected to enhance its market opportunities, driving performance growth over the next decade.
- Dexcom's Sustained Growth: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue in 2025, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing strong performance in diabetes management.
- Untapped Market Potential: Despite concerns over the popularity of GLP-1 weight loss drugs, Dexcom's management emphasizes that physicians prescribe CGM devices alongside these therapies, and the vast global market remains largely untapped, promising long-term returns for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm promises to handle cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees, thereby reducing the financial burden and encouraging more shareholders to participate.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately increases shareholder value and has significant strategic implications.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
See More
DexCom Announces Q1 2026 Financial Results Release Plan
- Earnings Release Schedule: DexCom plans to release its Q1 2026 financial results after market close on April 30, 2026, highlighting the company's ongoing innovation and development in diabetes management.
- Conference Call Details: Management will hold a conference call at 4:30 PM (Eastern Time) on the same day to review the first quarter performance, which is expected to attract significant attention from investors and analysts.
- Webcast Support: The conference call will be concurrently webcast, allowing investors to access the information through DexCom's investor relations website, ensuring transparency and accessibility of information.
- Company Background: Founded in 1999, DexCom has pioneered glucose biosensing technology for over 25 years, dedicated to empowering individuals to manage diabetes more effectively and improve their quality of life.
See More
